Zobrazeno 1 - 10
of 21
pro vyhledávání: '"E. G. Lomaia"'
Autor:
D. V. Kustova, E. V. Motyko, A. N. Kirienko, T. N. Gert, I. V. Leppyanen, M. P. Bakay, E. V. Efremova, E. V. Morozova, E. G. Lomaia, V. A. Shuvaev, S. V. Sidorkevich, I. S. Martynkevich
Publikováno v:
Онкогематология, Vol 19, Iss 3, Pp 45-60 (2024)
Background. Most patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors achieve durable optimal responses. Loss of the achieved molecular response is observed in 15–30 % of patients. Mutations in the BCR::ABL kinase do
Externí odkaz:
https://doaj.org/article/521725f71f1941fc829156dab8fb0afe
Publikováno v:
Онкогематология, Vol 0, Iss 1, Pp 5-20 (2022)
Imatinib (IM) appearance has changed approaches to chronic myeloid leukemia (CML) therapy. Second generation tyrosine kinase inhibitors (TKI) — nilotinib and dasatinib, developed soon after IM, and are already widely used in CML patients with ineff
Externí odkaz:
https://doaj.org/article/202d0cb6000e4d1db51acf67934d8ead
Autor:
E. G. Lomaia, A. Y. Zaritskey
Publikováno v:
Онкогематология, Vol 0, Iss 4, Pp 67-72 (2022)
Externí odkaz:
https://doaj.org/article/9db3b5e726f9451eb3946ab4b706c401
Publikováno v:
Онкогематология, Vol 0, Iss 2, Pp 4-16 (2022)
The first successful experience effective target therapy has been achieved at imatinib administration in chronic myeloid leukemia (CML) treatment. Disease early considered practically incurable, now successful controlled using little toxic conservati
Externí odkaz:
https://doaj.org/article/d220e9cc9f334285b05ca47e07bc30cf
Publikováno v:
Онкогематология, Vol 0, Iss 3, Pp 40-56 (2022)
Externí odkaz:
https://doaj.org/article/1579ec1c1bde4d438fe4c4eb9c996c67
Autor:
K. V. Naumova, I. L. Davydkin, E. G. Lomaia, T. Yu. Stepanova, T. P. Kuzmina, D. B. Zammoyeva
Publikováno v:
Российский кардиологический журнал, Vol 25, Iss 4S (2021)
CML), the accepting inhibitors tyrosine of kinases (TKI) I and the II generations (TKI1 and TKI2 respectively), and development of arterial hypertension.Material and methods. Examination of 137 patients with CML in the chronic phase (CP) is conducted
Externí odkaz:
https://doaj.org/article/7a98715a5136464fb8bd9a1692a72351
Autor:
E. G. lisina, N. T. Siordiya, P. A. Butylin, A. A. Silyutina, N. M. Matyukhina, O. M. Senderova, E. S. Fokina, V. A. Ovsepyan, E. G. Lomaia, A. Yu. Zaritskiy
Publikováno v:
Онкогематология, Vol 12, Iss 3, Pp 8-16 (2017)
Introduction. JAK2V617F mutation is detected in approximately 50 % of patients with essential thrombocytosis (ET) and primary myelofibrosis (PMF). In 2013 most of the JAK2 negative patients showed mutations in the CALR gene. Diagnostic value of JAK2
Externí odkaz:
https://doaj.org/article/4cbcde7263a74b05a482b52c9b4815e2
Autor:
T. I. Ionova, T. P. Nikitina, E. G. Lomaia, G. B. Kuchma, E. R. Machyulaytene, E. I. Usacheva, T. V. Shnaider, A. Yu. Rodionova, K. A. Kurbatova
Publikováno v:
Онкогематология, Vol 10, Iss 3, Pp 18-27 (2015)
The article is focused on the results of the multicenter observational study “Quality of life and symptom profile in patients with chronic myeloid leukemia in chronic phase in long-term follow-up of second-line treatment” (2012–2015). Thirty im
Externí odkaz:
https://doaj.org/article/c8680f87776e4102893c994d17475b74
Publikováno v:
Онкогематология, Vol 8, Iss 2, Pp 22-33 (2014)
Current treatment options for chronic myeloid leukemia (CML) with imatinib allowed achieving long-term progression-free and overall survival and improved patient quality of life. In cases of imatinib resistance therapy with second-generation tyrosine
Externí odkaz:
https://doaj.org/article/6315c5b7c05547599f9bd6d54888c699
Autor:
K. V. Bogdanov, O. V. Merzlikina, Y. V. Mirolyubova, L. L. Girshova, E. G. Lomaia, A. Y. Zaritskey
Publikováno v:
Molecular Biology. 55:121-132
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::04647f9281d58d1e7c17c93f4c3a9945
https://doi.org/10.1134/s0026893321010027
https://doi.org/10.1134/s0026893321010027